Mark down another failure in the battle against Alzheimer’s disease.

Roche (RHHBY) announced Wednesday morning that it is stopping two clinical trials of a drug it is developing to try to prevent the worsening of Alzheimer’s by targeting protein fragments known as beta-amyloid, which scientists have long believed are a key cause of the brain-destroying disorder. It adds to a heap of failures that includes efforts by just about every large drug company. No medicine has ever been shown to significantly slow Alzheimer’s, and the field has had no successes at all in more than a decade.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • There are differences between the above mentioned antibodies that target different subclasses of amyloid protein. Drug discovery is filled with stories where subtle differences in molecules give remarkable differences in outcome. Agree with the other comment that there is likely a significant immune component to Alzheimer’s- whether triggered by infectious disease, abberant signalling or something else.

  • The anti-amyloid drug candidates don’t seem to be working. It’s time for Big Pharma and government research funders to open their minds and act on the clues suggesting that infectious agents are the triggers of Alzheimer’s.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy